Inhibikase Therapeutics Inc.

IKT | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.31

+$0.11 (+5.00%)

At close: Sep 22, 2026, 4:00 PM ET

$2.31

$0 (0.00%)

After-hours: Sep 22, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+5.00%

(1D)

Rating

Updated: Sep 11, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $305M

1D Range

2.21 2.34

52W Range

1.33 2.61

Valuation (TTM)

PE -4.58

PB 1.89

EV/EBITDA -2.11

Valuation (NTM)

Forward PE N/A

Forward PEG -0.75

Price Target $6.50

Cash Flow

FCF Yield -14.8%

SBC Adj. FCF Yield -21.7%

SBC Impact -46.4%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -150.0% | -71.2%

Dil EPS 3Y | 5Y 72.6% | 38.3%

FCF 3Y | 5Y -50.2% | -25.2%

Returns

ROA -37.1%

ROE -42.8%

ROIC -42.9%

Financial Health

Net Cash

$159.02M

Current Ratio 15.82

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arteria...

Sector Healthcare

Industry Biotechnology

Employees 35

IPO Date Dec 22, 2020

Website www.inhibikase.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.